Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2020)

Historic Gains from Sales and Divestitures for Outlook Therapeutics (OTLK) over the last 3 years, with Q2 2020 value amounting to $109.0.

  • Outlook Therapeutics' Gains from Sales and Divestitures changed N/A to $109.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $109.0, marking a year-over-year change of. This contributed to the annual value of $4069.0 for FY2019, which is 9613.8% down from last year.
  • As of Q2 2020, Outlook Therapeutics' Gains from Sales and Divestitures stood at $109.0.
  • Over the past 5 years, Outlook Therapeutics' Gains from Sales and Divestitures peaked at $105361.0 during Q3 2018, and registered a low of $109.0 during Q4 2019.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $109.0 (2019), whereas its average is $21951.4.
  • Examining YoY changes over the last 5 years, Outlook Therapeutics' Gains from Sales and Divestitures showed a top increase of 9613.8% in 2019 and a maximum decrease of 9613.8% in 2019.
  • Outlook Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $105361.0 in 2018, then plummeted by 99.9% to $109.0 in 2019, then changed by 0.0% to $109.0 in 2020.
  • Its last three reported values are $109.0 in Q2 2020, $109.0 for Q1 2020, and $109.0 during Q4 2019.